TRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis

Trial Profile

TRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2015

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Cardiovascular disorders
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms TRACE-RA; TRACE-RA-Biobank; TRACE-RA-DAS
  • Most Recent Events

    • 13 Jun 2015 The trial had been discontinued according to the abstract presented at 16th Annual Congress of the European League Against Rheumatism.
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism (n = 2986).
    • 20 Mar 2015 Accrual to date 60% reported by United Kingdom Clinical Research Network record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top